



Syva Emit II Plus Buprenorphine Assay

Compliance Monitoring in Medically Assisted Opioid Addiction Treatment

H. Roma Levy, MS

[siemens-healthineers.com](https://www.siemens-healthineers.com)

Compliance Monitoring in Medically Assisted Opioid Addiction Treatment: The Siemens Healthineers Syva Emit II Plus Buprenorphine Assay

Introduction

Worldwide opioid addiction has increased dramatically in the last decade, with the greatest rise documented in the U.S.¹⁻³ A primary factor driving this growth is the increasing use of prescription opioids (e.g., oxycodone, hydrocodone, and morphine) for chronic pain in response to the American Pain Society's assertion that pain should be assessed as the "fifth vital sign" in outpatient care.^{4,5} Recreational use of heroin also continues to contribute to opioid addiction. In the U.S. alone, heroin use almost doubled between 2002 and 2014, from 1.6/1000 persons ≥ 12 years of age to 2.6/1000 persons. Illegally obtained prescription opioids serving as gateway drugs attribute to approximately 80% of this population.² Conversely, previous heroin use accounts for only 20% of prescription opioid abuse.²

Opioid Chemistry and Physiologic Effects

Opioid drugs are derived from the opium poppy, *Papaver somniferum*. First cultivated by the Sumerians and named "Hul Gil" (the joy plant), opium and derivative drugs have been used for over five millennia, both medically (analgesia, sedation) and recreationally (euphoria).⁶ Naturally derived and semisynthetic opioids share a similar structure, while synthetic opioids do not

(Figure 1).⁷ Their primary agonist targets are mu receptors. These drugs can also cause depressed respiration, slowed or rapid heart rate, and reduced gastric motility.⁷ Overdose due to cardio-pulmonary effects can be fatal.

All opioid effects are in response to drug stimulation of mu receptors, which are found in the brain, spinal cord, and gastrointestinal tract. The natural mu receptor agonist is β -endorphin ("endogenous morphine"), a 31-amino acid neuropeptide/neurohormone.^{8,9} When released in the central nervous system (CNS), β -endorphin interacts with the mesolimbic reward system. This system uses positive reward to reinforce learning and behavior necessary for survival. When β -endorphin activates the mu receptor in response to enjoyable input, dopamine is released and stimulates specific brain loci. Some of these loci trigger sensations of pleasure and desire, while others evaluate the benefit of repeating the behavior. When it interacts with synapses in the peripheral nervous system (PNS), β -endorphin acts as a natural pain killer. Feeling "normal" depends on regular low-level stimulation of PNS mu receptors by β -endorphin, and without it, even a minor injury such as a stubbed toe would register as incapacitating pain.^{8,10,11}






Figure 1. Structural similarity between β -endorphin and natural and synthetic opioids. Red indicates how each natural or semisynthetic molecule differs from morphine.

Figure 2. Agonist and antagonist binding at the mu receptor.²³Figure 3. Mu receptor activity depending on ligand.²²

Addiction


Hijack of the CNS and PNS mu receptor functions by either prescription or illicit opioids can cause addictive behavior in genetically and environmentally susceptible individuals.^{10,12,14} Opioid addiction includes both physiologic drug dependence (drug is needed to replace non-pain-related PNS stimulation by β -endorphin) and physical and psychological cravings (CNS loci associated with cravings and reward value require constant stimulation). Tolerance develops with continued drug use, requiring ever-increasing dosage to achieve both euphoric effects and feelings of physical normalcy. Because most opioid drugs are short-acting, with effects lasting from only a few hours to 8 hours, addicted users cycle constantly through peaks of physical well-being and valleys of minor to severe withdrawal symptoms.^{7,15} Continued use of opioids—especially pharmaceutical-grade opioids—can result in changes to brain chemistry and morphology, resulting in down-regulation of β -endorphin synthesis and increasing or total dependence on exogenous drugs.^{10,13}

Medically Assisted Opioid Addiction Therapy

Because of damage caused to the normal endorphin-producing cells, opioid addiction is considered a chronic brain disease and may require lifelong drug treatment and management.¹⁶ Medically assisted therapy (MAT) uses drugs such as buprenorphine (BUP) to prevent the negative symptoms of withdrawal and ease dependency and cravings until normal brain chemistry is restored, if possible.¹⁶⁻¹⁹ MAT is a more effective option for treating addiction than methods that do not employ medication.^{15,17,20,21}

BUP is derived from the natural opium alkaloid Thebaine (Figure 1). As a partial mu agonist, BUP has high affinity for the mu receptor, preferentially binding to it over other opioids.^{15,22,23} It both displaces other opioids bound by receptors and prevents new molecules from binding (Figure 2).²³ Because it has low physiological activity, euphoric effects are minimized when taken as intended (Figure 3).^{7,19,24,25} The “high” associated with other opioids diminishes rapidly with repeated administration of sublingual or transdermal BUP and cannot be induced by taking increasing doses when administered correctly (ceiling effect).²⁴ This ceiling effect also reduces the risk of respiratory depression, bradycardia, and overdose.¹⁹

Despite this, BUP itself is subject to abuse through diversion (circumvention) of the drug’s appropriate use. Diversion includes inappropriate drug administration (inhaling, smoking, or injection), selling prescribed pills to purchase other opioids (potentially because treatment dose is insufficient, especially in early treatment), and skipping doses to take other opioids.^{1,5,26-30} Other predominant reasons include sharing prescriptions with others who don’t have access to care and are trying to self-treat, hoarding pills to use at a higher dosage, and selling a portion of the prescription to finance addiction treatment costs.^{5,27,31-34} BUP combined with naloxone (trade name SUBOXONE) reduces—but does not eliminate—diversion risk by inhalation or injection because administration of naloxone by these methods causes immediate and severe withdrawal symptoms.^{28,31-33}

Figure 4. BUP and its major metabolites.^{42,44}

Buprenorphine Testing

Buprenorphine urine testing is valuable both clinically and in the emergency department when screening for abused substances. The American Society of Addiction Medicine (ASAM) recommends urine drug testing throughout MAT to assess compliance and promote longterm recovery; more frequent testing is suggested during early treatment and if the patient relapses.^{15,18,35,36} Patients treated in opioid treatment programs (OTP) must be administered at least eight drug tests annually according to U.S. federal law, but no recommendations exist for treatment through a private physician's office. Oral BUP is prescribed both on- and off-label for chronic pain control in many countries, and periodic random monitoring is also suggested.³⁶⁻³⁸

Because of their low cost, easy accessibility, and high throughput, immunoassays (IAs) are useful for primary screening. Urine concentration of BUP may be below the

detection limit of most assays, therefore assays are designed to detect BUP and at least one of its three major metabolites: norbuprenorphine (norBUP), buprenorphine glucuronide (BUP-G), and norbuprenorphine glucuronide (norBUP-G). These metabolites (Figure 4) are typically excreted in urine at concentrations many times greater than the parent drug (Figure 5).^{35,39-47} Furthermore, urinary levels of the parent drug can decline appreciably in a matter of hours, which can make identification difficult in an emergent situation; however all three metabolites can be detected in the absence of BUP and remain detectable for at least 4 days after sublingual administration (Figure 6).^{40,42-45,48} Gas (GC) or liquid (LC) chromatography followed by tandem mass spectrometry (MS/MS) is used to confirm IA results and to determine the ratio of NorBUP:BUP as an indicator of sample adulteration (addition of crushed BUP).^{35,43,49}




Figure 5. Percentage of BUP and major metabolites measured using LC/high-resolution MS in the urine of 20 MAT patients. The sample containing only BUP indicates probable adulteration with crushed drug (adapted from Belsey, et al.).⁴⁰




Figure 6. Changes in urine BUP and norBUP determined using LC/MS/MS in a single subject following ingestion of a single 2 mg dose of BUP (adapted from Regina, et al.).⁴⁵

The Siemens Healthineers Assay and Assays from Other Manufacturers

The Siemens Healthineers Syva® Emit® II Plus Buprenorphine Assay for the Viva™ Drug Testing Systems detects both BUP and norBUP. Results can be reported both qualitatively and semiquantitatively based on a 5 ng/mL cut-off.⁵⁰ For both usages, positive agreement (PA) between the assay and LC/MS/MS is 90% and negative agreement (NA) is 98%.⁵¹

Four other commercial BUP IAs are currently available. All four can be used either qualitatively or semiquantitatively, and all show good positive and negative agreement with tandem mass spectrometry according to their package inserts (Table 1).⁵²⁻⁵⁵ The Siemens Healthineers assay performs at least comparably to all of these assays with respect to positive and negative agreement with tandem mass spectrometry, and its detection cutoff is lower than either the Lin-Zhi EIA or Thermo Fisher CEDIA Buprenorphine II assays. Although positive agreement with LC/MS/MS is lower for the Siemens Healthineers assay than reported by other manufacturers, this is because we chose to challenge the assay by testing many samples having a BUP concentration very close to the 5 ng/mL cutoff.

Because of the structural similarity between BUP and other opioids, high antibody specificity for BUP and its metabolites is necessary to reduce the likelihood of falsepositive results. Twenty-two common opioids and metabolites demonstrated <0.01% cross-reactivity with the Emit assay at a concentration of 100,000 ng/mL. In addition, a wide range of structurally unrelated compounds and over-the-counter medications did not interfere with assay results above the 5 ng/mL cutoff.

In contrast, several independent evaluations of the original CEDIA assay conducted between 2005 and 2014, including information reported by the manufacturer, indicated up to 40% cross-reactivity with other opioids and structurally dissimilar and unrelated drugs at therapeutic levels (e.g., antimalarial/immune modulators chloroquine and hydroxychloroquine and antipsychotics sulpride and amisulpride).^{41,44,46,56-59} Detection of these compounds generated false-positive results above the 5 ng/mL cutoff. While specificity of the newly released CEDIA Buprenorphine II assay has improved, it comes at the expense of sensitivity. The cutoff for this new assay has been increased to 10 ng/mL.⁵⁵

Table 1. Commercially available BUP immunoassays. Unless specifically cited, all information was obtained from each manufacturer's package insert or data sheet.

Manufacturer/ Assay Name	Metabolites Detected (cross-reactivity)	Cut-off (ng/mL)	Measurable Range (ng/mL)	MS/MS Agreement				Tests within 50% above the cut-off: (Range – ng/mL) (%) (Total Pos/Total)	
				Qualitative		Semi- Quantitative		Qualitative	Semi- Quantitative
				Pos (%)	Neg (%)	Pos (%)	Neg (%)		
Siemens Healthineers Emit II Plus Buprenorphine Assay	BUP (100%) norBUP (92.6%) BUP-G (0.1%) norBUP-G (0.1%)	5	0.7–25	90	98	90	98	5.0–7.5 94.1 16/17	5.0–7.5 94.1 16/17
Thermo Fisher (Microgenics) CEDIA Buprenorphine Assay	BUP (100%) BUP-G (98%) norBUP (<0.015%) norBUP-G (<0.015%)	5	1.25–75	100	98	N/A ^a	N/A	N/A	N/A
Thermo Fisher (Microgenics) CEDIA Buprenorphine II Assay	norBUP (125%) BUP (100%) norBUP-G (100%) BUP-G (76.9%)	10	Not specified – 100	98.9 ^b	100	100 ^b	100	10–15.0 100 5/5	10–15.0 100 5/5
Lin-Zhi International, Inc. Buprenorphine Enzyme Immunoassay (EIA)	norBUP (100%) BUP (94.3%) norBUP-G (0.97%) BUP-G (0.03%)	10	3–70	97.4	95.3	N/A	N/A	10–15.0 75 6/8	N/A
Immunalysis Buprenorphine Homogeneous Enzyme Immunoassay (HEIA)	BUP (100%) norBUP (90.91%) BUP-G (0.17%) norBUP-G (0.13%)	5	0.6–40 ^c	100	100	100	100	5.0–7.5 100 4/4	5.0–7.5 100 4/4

a. N/A indicates information is not available.

b. Includes contribution of measured metabolites

c. LoD per Belsey et al.⁴⁰ to high calibrator from package insert.

Direct Comparison of the Siemens Healthineers Emit Assay to the Immunalysis HEIA Assay

A head-to-head comparison study was conducted between the Siemens Healthineers Emit and Immunalysis HEIA assays (Table 2).⁶⁰ Overall agreement was 92%. Negative agreement was 100% when compared both qualitatively and semiquantitatively. Positive agreement was lower at 87% due to eight discordant samples that were negative according to the Siemens Healthineers assay and positive according to HEIA. Upon further analysis using ID-LC/MS/MS, all eight samples were found to be negative and therefore in agreement with the results obtained with the Siemens Healthineers assay (Table 3). It is possible that this difference reflects slightly higher cross reactivity for norBUP by the Siemens Healthineers assay. Regardless, these data suggest that the Siemens Healthineers assay performs at least as well as the Immunalysis assay.

Summary

- The opioid epidemic presents an ongoing worldwide health crisis. Opioid addiction is difficult to overcome without the aid of medically assisted therapy.
- Buprenorphine is a partial mu agonist used in medically assisted therapy, and random periodic urine testing is recommended to assess compliance and correct dosing.
- Buprenorphine immunoassays provide only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas chromatography/tandem mass spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS/MS) are the preferred confirmatory methods.
- Immunoassays should be able to detect buprenorphine and some combination of its metabolites at a sensitivity that shows good positive agreement with mass spectrometry.
- Immunoassays should be highly specific to reduce false positives resulting from cross-reactivity with other structurally similar opioids and structurally dissimilar non-opioid drugs that might be taken during therapy.
- The Siemens Healthineers Emit II Plus Buprenorphine Assay is both sensitive and specific, and demonstrates good positive and negative agreement with LC/MS/MS and the Immunalysis HEIA assay.

Table 2. Comparison of the Siemens Healthineers Emit assay to the Immunalysis HEIA assay.

		Siemens Healthineers Emit Assay				% Agreement
		Neg (< 2.5 ng/mL)	Neg Within 50% below the Cut-off (2.5–4.9 ng/mL)	Pos Within 50% above the Cut-off (5.0–7.5 ng/mL)	Pos (> 7.5 ng/mL)	
Qualitative	Immunalysis Pos	0	8	11	43	87
	Immunalysis Neg	35	3	0	0	100
Semiquantitative	Immunalysis Pos	0	8	11	43	87
	Immunalysis Neg	35	3	0	0	100

Table 3. ID-LC/MS/MS evaluation of discordant results.

Sample ID	ID-LC/MS/MS results (ng/mL)			Siemens Healthineers Emit Assay (ng/mL)	Immunalysis HEIA (ng/mL)	Final Interpretation		
	BUP	norBUP	Total			ID-LC/MS/MS	Emit	HEIA
1	0	4.23	4.23	4.8	7.1	Neg	Neg	Pos
2	0	4.24	4.24	4.9	7.2	Neg	Neg	Pos
3	0	3.50	3.50	3.9	5.6	Neg	Neg	Pos
4	0	4.02	4.02	4.8	7.3	Neg	Neg	Pos
5	0	3.04	3.04	3.5	5.2	Neg	Neg	Pos
6	0	3.06	3.06	3.5	5.5	Neg	Neg	Pos
7	0	3.65	3.65	3.8	5.7	Neg	Neg	Pos
8	0	4.15	4.15	4.9	7.3	Neg	Neg	Pos

References:

1. United Nations Office on Drugs and Crime. World Drug Report. New York, NY, USA 2016.
2. Jones CM, Logan J, Gladden RM, Bohm MK. Vital Signs: Demographic and Substance Use Trends Among Heroin Users – United States, 2002–2013. *MMWR Morb Mortal Wkly Rep* 2015;64:719–25.
3. Rudd R, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2010–2015. *MMWR* 2016;65:1445–52.
4. Pain: Current Understanding of Assessment, Management, and Treatments. 2000. Accessed July 27, 2017. Available at http://americanpainsociety.org/uploads/education/section_2.pdf.
5. Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. *Curr Drug Abuse Rev* 2011;4:28–41.
6. Cannabis, Coca, & Poppy: Nature's Addictive Plants. Accessed July 27, 2017. Available at <https://www.deamuseum.org/ccp/opium/history.html>.
7. Opiates/Opioids. 2017. Available July 27, 2017. Available at https://www.naabt.org/education/opiates_opioids.cfm.
8. Roth-Deri I, Green-Sadan T, Yadid G. Beta-endorphin and drug-induced reward and reinforcement. *Prog Neurobiol* 2008;86:1–21.
9. Sobczak M, Salaga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. *J Gastroenterol* 2014;49:24–45.
10. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. *Physiol Rev* 2009;89:1379–412.
11. Sprouse-Blum AS, Smith G, Sugai D, Parsa FD. Understanding endorphins and their importance in pain management. *Hawaii Med J* 2010;69:70–1.
12. Leppa M, Korvenoja A, Carlson S, et al. Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. *Neuroimage* 2006;31:661–9.
13. Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. *Brain* 2010;133:2098–114.
14. Mistry CJ, Bawor M, Desai D, Marsh DC, Samaan Z. Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence. *Curr Psychiatry Rev* 2014;10:156–67.
15. Comer S, Cunningham C, Fishman M, et al. National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. American Society of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 2015:1–66.
16. Substance Abuse and Mental Health Services Administration (SAMHSA). The Facts about Buprenorphine for Treatment of Opioid Addiction. 2009. Accessed July 5, 2017. Available at <http://store.samhsa.gov/shin/content/SMA09-4442/SMA09-4442.pdf>.
17. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N Engl J Med* 2003;349:949–58.
18. SAMHSA Federal Guidelines for Opioid Treatment Programs. 2015. Accessed July 5, 2017. Available at <https://store.samhsa.gov/shin/content/PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf>.
19. Pharmacology of Buprenorphine. 2017. Accessed July 7, 2017. Available at https://www.naabt.org/education/pharmacology_of_buprenorphine.cfm.
20. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev* 2014;CD002207.
21. Medication-Assisted Treatment Improves Outcomes for Patients With Opioid Use Disorder. The PEW Charitable Trusts, 2016. Accessed July 19, 2017. Available at <http://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2016/11/medication-assisted-treatment-improves-outcomes-for-patients-with-opioid-use-disorder>.
22. Welsh C, Valadez-Meltzer A. Buprenorphine: a (relatively) new treatment for opioid dependence. *Psychiatry (Edgmont)* 2005;2:29–39.
23. Manglik A, Kruse AC, Kobilka TS, et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. *Nature* 2012;485:321–6.
24. Whelan PJ, Remski K. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. *J Neurosci Rural Pract* 2012;3:45–50.
25. NAABT. Buprenorphine. A treatment for opioid addiction in the privacy of a doctor's office. 2015. Accessed July 5, 2017. Available at https://www.naabt.org/documents/naabt_brochure%20Version%202.pdf.
26. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. *Pain Med* 2010;11:1078–91.
27. Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. *Int J Drug Policy* 2008;19:450–8.
28. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? *Addiction* 2005;100:197–205.
29. Balhara YP, Jain R. A urinalysis-based study of buprenorphine and nonprescription opioid use among patients on buprenorphine maintenance. *J Pharmacol Pharmacother* 2012;3:15–9. 30. Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. *Int J Drug Policy* 2011;22:167–71.
31. Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. *Drug Alcohol Depend* 2008;97:105–13.
32. Roux P, Villes V, Bry D, et al. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. *Addict Behav* 2008;33:1625–9.
33. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine/naloxone tablets in untreated IV drug users. *Drug Alcohol Depend* 2007;88:75–8.
34. Martin J. Adherence, Diversion and Misuse of Sublingual Buprenorphine. Providence, RI: Providers' Clinical Support System for Medication Assisted Treatment; 2014.
35. SAMHSA. Clinical Drug Testing in Primary Care. 2012. Accessed July 5, 2017. Available at <https://store.samhsa.gov/shin/content/SMA12-4668/SMA12-4668.pdf>.
36. Group AW. Drug Testing: A White Paper of the American Society of Addiction Medicine (ASAM). American Society of Addiction Medicine; 2013:116.
37. CDC. CDC Guideline for Prescribing Opioids for Chronic Pain FAQ Sheet. Accessed July 19, 2017. Available at https://www.cdc.gov/drugoverdose/pdf/guidelines_at-a-glance-a.pdf.
38. Langman L, Jannetto P, Hammett-Stabler C, et al. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients (Rough Draft). 2016:103.
39. Beck O, Bosch T, Duncan C, et al. European Guidelines for Workplace Drug Testing in Urine. European Workplace Drug Testing Society 2015.
40. Belsey SL, Couchman L, Flanagan RJ. Buprenorphine detection in urine using liquid chromatography-high-resolution mass spectrometry: comparison with cloned enzyme donor immunoassay (ThermoFisher) and homogeneous enzyme immunoassay (Immunalysis). *J Anal Toxicol* 2014;38:438–43.
41. Berg JA, Schjott J, Fossan KO, Riedel B. Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids. *Subst Abuse Rehabil* 2015;6:131–9.
42. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. *Clin Pharmacokinet* 2005;44:661–80.
43. Hull MJ, Bierer MF, Griggs DA, Long WH, Nixon AL, Flood JG. Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. *J Anal Toxicol* 2008;32:516–21.
44. Melanson SE, Snyder ML, Jarolim P, Flood JG. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse. *J Anal Toxicol* 2012;36:201–6.
45. Regina KJ, Kharasch ED. High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci* 2013;939:23–31.

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare.

Emit, Syva, Viva, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

References:

46. Snyder ML, Darragh A, Flood JG, et al. Improved buprenorphine immunoassay performance after urine treatment with beta-glucuronidase. *J Anal Toxicol* 2014;38:375-9.
47. Vincent F, Bessard J, Vacheron J, Mallaret M, Bessard G. Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry. *J Anal Toxicol* 1999;23:270-9.
48. Depriest A, Heltsley R, Black DL, et al. Urine drug testing of chronic pain patients. III. Normetabolites as biomarkers of synthetic opioid use. *J Anal Toxicol* 2010;34:444-9.
49. LC-MS/MS Testing for Monitoring Compliance in Pain Management. AACC, 2016. Accessed July 19, 2017. Available at <https://www.aacc.org/publications/cln/articles/2016/february/lc-ms-ms-testing-for-monitoring-compliance-in-pain-management>.
50. Siemens Healthcare Diagnostics Inc. Syva Emit II Plus Buprenorphine Assay Package Insert, 10872256_A. 2-15.
51. Siemens Healthcare Diagnostics Inc. Emit II Plus Buprenorphine Assay Datasheet. Order number A91DX-HHS-160193-GC1-4A00. 2016.
52. Thermo Fisher Scientific. CEDIA Buprenorphine Assay Package Insert (10007988-8-EN). 2016.
53. Lin-Zhi International Inc. LZI Buprenorphine Enzyme Immunoassay Package Insert. 2016.
54. Immunalysis Corporation. Buprenorphine Homogeneous Enzyme Immunoassay (HEIA) Factsheet. 2014.
55. Thermo Fisher Scientific. CEDIA Buprenorphine II Assay Package Insert, 10020852-1-EN. Fremont, CA: Thermo Scientific; 2017.
56. Bottcher M, Beck O. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. *J Anal Toxicol* 2005;29:769-76.
57. Pavlic M, Libiseller K, Grubwieser P, Rabl W. Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon? *Int J Legal Med* 2005;119:378-81.
58. Thermo Fisher Scientific. CEDIA Buprenorphine Cross-Reactivity Table (Positive Compounds). 2011. Accessed July 27, 2017. Available at <https://static.thermoscientific.com/images/D15911~.pdf>.
59. Birch MA, Couchman L, Pietromartire S, et al. False-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpiride. *J Anal Toxicol* 2013;37:233-6.
60. Siemens Healthcare Diagnostics Inc. Customer Bulletin: Comparison Study for the EMIT II Plus Buprenorphine Assay 11312023, Rev. A. 2016.

Siemens Healthineers Headquarters

Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen, Germany
Phone: +49 9131 84-0
siemens-healthineers.com

Published by

Siemens Healthcare Diagnostics Inc.
Laboratory Diagnostics
511 Benedict Avenue
Tarrytown, NY 10591-5005
USA
Phone: +1 914-631-8000